Cognetivity Neurosciences Ltd

Ondine Biomedical Inc., based in Vancouver, BC, is a pioneering Canadian life sciences company specializing in photodisinfection technologies aimed at preventing and treating a wide range of infections, including those caused by drug-resistant pathogens. Their patented platform technology has demonstrated significant efficacy, achieving up to an 84% reduction in postoperative infection rates in major Canadian hospitals. The company's flagship product, Steriwave, offers rapid nasal decolonization, effectively eradicating a broad spectrum of pathogens within minutes, thereby reducing the risk of healthcare-associated infections. Ondine is also actively developing additional products targeting chronic rhinosinusitis, wound disinfection, and antiviral therapies for the upper respiratory tract. Generated from the website

HAVN Life Sciences Inc is a Vancouver-based biotechnology company focused on advancing psychedelic medicine to support mental health and wellness. With a mission to empower individuals through innovative therapies, HAVN Life is dedicated to unlocking human performance and enabling people to reach their full potential. Through its subsidiary, HAVN Labs, the company is actively developing a psychedelics supply chain for clinical researchers, emphasizing the standardized extraction, formulation, and delivery of psychedelics. As part of a global community, HAVN Life is contributing to research on microdosing therapies that have shown promise in addressing mental health issues and enhancing performance. Generated from the website

AbCellera is a biotechnology company based in Vancouver, British Columbia, that focuses on developing innovative antibody-based medicines through a unique platform integrating biology, computation, and engineering. With a growing team of over 600 professionals, the company aims to address significant challenges in healthcare by delivering first-in-class and best-in-class therapeutic solutions for various medical conditions. Since its inception, AbCellera has partnered with more than 40 collaborators on 100 antibody drug programs, demonstrating its commitment to pushing the limits of science and technology in medicine. The company's research pipeline includes promising candidates for treating conditions such as vasomotor symptoms associated with menopause and moderate-to-severe atopic dermatitis, reflecting its dedication to improving patient health and well-being. Generated from the website